Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
ULTANE (sevoflurane) is a volatile general anesthetic administered by inhalation for induction and maintenance of anesthesia in surgical and procedural settings. It is a small-molecule, non-halogenated ether that works as a central nervous system depressant to produce unconsciousness and analgesia. The drug is used across diverse patient populations requiring general anesthesia.
As LOE approaches, the brand team is likely consolidating around core maintenance and market defense with limited growth headroom; expect a compact, focused commercial organization.
General Anesthetic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Transition From Sevoflurane to Total Intravenous Anesthesia in Pediatric Patients
Does Boredom With Simultaneously Perceived Pain Affect Pressure Pain Thresholds
Sevoflurane Sedation in Patients With Septic Shock
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Assessment of Hard and Soft Tissue Changes Following XCM Versus FGG Simultaneous With Delayed Dental Implant Placement
Worked on ULTANE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ULTANE offers exposure to mature-market commercial strategy, account management, and hospital/healthcare system relationships in the anesthesia space. This is a stabilization and profitability-focused role rather than a growth or launch opportunity, suited for professionals seeking deep expertise in a cornerstone therapeutic category.
1 open roles linked to this drug